Prudential Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-61,459
Closed -$7.32M 2570
2024
Q3
$7.32M Sell
61,459
-1,785
-3% -$238K 0.01% 810
2024
Q2
$9.03M Buy
63,244
+3,965
+7% +$525K 0.01% 678
2024
Q1
$7.61M Buy
59,279
+5,257
+10% +$626K 0.01% 766
2023
Q4
$5.59M Buy
54,022
+4,069
+8% +$402K 0.01% 882
2023
Q3
$4.54M Buy
49,953
+357
+0.7% +$31.4K 0.01% 935
2023
Q2
$4.01M Buy
49,596
+14,776
+42% +$1.21M 0.01% 1005
2023
Q1
$1.94M Buy
34,820
+554
+2% +$39.3K ﹤0.01% 1362
2022
Q4
$2.32M Buy
34,266
+1,830
+6% +$107K ﹤0.01% 1230
2022
Q3
$1.63M Buy
32,436
+2,588
+9% +$139K ﹤0.01% 1458
2022
Q2
$1.64M Buy
29,848
+14,520
+95% +$806K ﹤0.01% 1504
2022
Q1
$851K Buy
15,328
+4,344
+40% +$223K ﹤0.01% 1950
2021
Q4
$636K Sell
10,984
-152
-1% -$8.23K ﹤0.01% 2107
2021
Q3
$565K Buy
11,136
+1,180
+12% +$57K ﹤0.01% 2099
2021
Q2
$417K Buy
9,956
+528
+6% +$20.5K ﹤0.01% 2193
2021
Q1
$318K Buy
9,428
+60
+0.6% +$2.14K ﹤0.01% 2259
2020
Q4
$327K Buy
9,368
+1,688
+22% +$58.3K ﹤0.01% 2219
2020
Q3
$267K Buy
7,680
+1,270
+20% +$42.3K ﹤0.01% 2204
2020
Q2
$210K Buy
+6,410
New +$205K ﹤0.01% 2246

Other funds holding NVO

Prudential Financial's NVO Position: Q4 2024 in Review

Prudential Financial sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 61,459 shares — an estimated $7.32M sold.

Prudential Financial first reported a position in NVO in Q2 2020 and held it in 18 quarters. The position peaked at $9.03M in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Prudential Financial reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Prudential Financial sold 61,459 Novo Nordisk shares in Q4 2024, an estimated $7.32M.
  • Prudential Financial first reported a position in Novo Nordisk in Q2 2020 and held it in 18 quarters.
  • Prudential Financial's Novo Nordisk position peaked at $9.03M in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Prudential Financial's 13F filing for Q4 2024, filed 11 Feb 2025.